Association of cystatin-C with metabolic syndrome in normal glucose-tolerant subjects (CURES-97)

Diabetes Technology and Therapeutics

Volumn 12, Issue 11, 2010, Pages 907-912

  Surendar, Jatagopi ^a   Indulekha, K ^a   Aravindhan, V ^a   Ganesan, Anbazaghan ^a   Mohan, Vishwanathan ^a  

^a MADRAS DIABETES RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATIN C;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; INDIA; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NEPHELOMETRY; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

ADULT; ALBUMINURIA; ANTHROPOMETRY; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD PRESSURE; CYSTATIN C; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INDIA; KIDNEY FUNCTION TESTS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS;

EID: 78649356694     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0077     Document Type: Article

References (42)

1. Ford ES, Li C, Cook S, Choi HK: Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation 2007;115:2526-2532.
2. Hu G, Lindström J, Jousilahti P, Peltonen M, Sjöberg L, Kaaja R, Sundvall J, Tuomilehto J: The increasing prevalence of metabolic syndrome among Finnish men and women over a decade. J Clin Endocrinol Metab 2008;93:832-836.
3. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004;27:2444-2449.
4. Li ZY, Xu GB, Xia TA: Prevalence rate of metabolic syndrome and dyslipidemia in a large professional population in Beijing. Atherosclerosis 2006;184:188-192.
5. Deepa M, Farooq S, Datta M, Deepa R, Mohan V: Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES-34). Diabetes Metab Res Rev 2007;23:127-134.
6. Enas EA, Mohan V, Deepa M, Farooq S, Pazhoor S, Chen-nikkara H: The metabolic syndrome and dyslipidemia among Asian Indians: a population with high rates of diabetes and premature coronary artery disease. J Cardiometab Syndr 2007;2:267-275.
7. Turk V, Bode W: The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett 1991;22;285:213-219.
8. Surendar J, Anuradha S, Ashley B, Balasubramanyam M, Aravindhan V, Rema M, Mohan V: Cystatin C and cystatin glomerular filtration rate as markers of early renal disease in Asian Indian subjects with glucose intolerance (CURES-32). Metab Syndr Relat Disord 2009;7:419-425.
9. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA: Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999;104:1191-1197.
10. Song SH, Kwak IS, Kim YJ, Lee HS, Rhee H, Lee DW, Kang YH, Kim SJ: Serum cystatin C is related to pulse wave velocity even in subjects with normal serum creatinine. Hy-pertens Res 2008;31:1895-1902.
11. Maahs DM, Ogden LG, Kretowski A, Snell-Bergeon JK, Kinney GL, Berl T, Rewers M: Serum cystatin C predicts progression of subclinical coronary atherosclerosis in individuals with type 1 diabetes. Diabetes 2007;56:2774-2779.
12. Shlipak MG, Katz R, Kestenbaum B, Fried LF, Siscovick D, Sarnak MJ: Clinical and subclinical cardiovascular disease and kidney function decline in the elderly. Atherosclerosis 2009;204:298-303.
13. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
14. Shlipak MG, Wassel Fyr CL, Chertow GM, Harris TB, Kritchevsky SB, Tylavsky FA, Satterfield S, Cummings SR, Newman AB, Fried LF: Cystatin C and mortality risk in the elderly: the health, aging, and body composition study. J Am Soc Nephrol 2006;17:254-261.
15. Koenig W, Twardella D, Brenner H, Rothenbacher D: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005;51:321-327. (Pubitemid 40175801)
16. Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, Newman AB, Siscovick D, Psaty BM, Sarnak MJ: Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 2005;45:268-271.
17. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L: Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110:2342-2348.
18. Ni L, Lü J, Hou LB, Yan JT, Fan Q, Hui R, Cianflone K, Wang W, Wang DW: Cystatin C, associated with hemorrhagic and ischemic stroke, is a strong predictor of the risk of cardiovascular events and death in Chinese. Stroke 2007;38:3287-3288.
19. Retnakaran R, Connelly PW, Harris SB, Zinman B, Hanley AJ: Cystatin C is associated with cardiovascular risk factors and metabolic syndrome in Aboriginal youth. Pediatr Nephrol 2007;22:1007-1013.
20. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C: Is serum cystatin-C a reliable marker for metabolic syndrome? Am J Med 2008;121:426-432.
21. Demircan N, Gurel A, Armutcu F, Unalacak M, Aktunc E, Atmaca H: The evaluation of serum cystatin C, mal-ondialdehyde, and total antioxidant status in patients with metabolic syndrome. Med Sci Monit 2008;14:CR97-CR101.
22. Deepa R, Gokulakrishnan K, Mohan V: Coronary artery disease among Indian diabetic subjects. In: Mohan V, Rao GHR, eds. Type 2 Diabetes in South Asians: Epidemiology, Risk Factors and Prevention. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd., 2006:242-255.
23. Deepa M, Pradeepa R, Rema M, Mohan A, Deepa R, Shan-thirani S, Mohan V: The Chennai Urban Rural Epidemiology Study (CURES)\study design and methodology (urban component) (CURES-I). J Assoc Physicians India 2003;51: 863-870.
24. Rema M, Mohan V, Deepa R, Ravikumar R: Association of carotid intima-media thickness and arterial stiffness with diabetic retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2). Chennai Urban Rural Epidemiology Study-2. Diabetes Care 2004;27:1962-1967.
25. Unnikrishnan RI, Rema M, Pradeepa R, Deepa M, Shan-thirani CS, Deepa R, Mohan V: Prevalence and risk factors of diabetic nephropathy in an urban South Indian population: the Chennai Urban Rural Epidemiology Study (CURES 45). Diabetes Care 2007;30:2019-2024.
26. Varghese A, Deepa R, Rema M, Mohan V: Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India. Postgrad Med J 2001;77:399-402.
27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
28. World Health Organization Western Pacific Region World Health Organization; International Association for the Study of Obesity; International Obesity Task Force: The Asia Pacific Perspective: Redefining Obesity and Its Treatment. Sydney: Health Communications Australia Pty Ltd., 2000:17-21.
29. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-470.
30. Donahue RP, Stranges S, Rejman K, Rafalson LB, Dmo-chowski J, Trevisan M: Elevated cystatin C concentration and progression to pre-diabetes: the Western New York study. Diabetes Care 2007;30:1724-1729.
31. Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P; PRIME Study Group: Plasma cystatin-C and development of coronary heart disease: the PRIME Study. Atherosclerosis 2006;185:375-380.
32. Wasén E, Isoaho R, Mattila K, Vahlberg T, Kivelä SL, Irjala K: Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 2003;42:36-43.
33. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65: 1416-1421.
34. Muntner P, Winston J, Uribarri J, Mann D, Fox CS: Overweight, obesity, and elevated serum cystatin C levels in adults in the United States. Am J Med 2008;121:341-348.
35. Naour N, Fellahi S, Renucci JF, Poitou C, Rouault C, Bas-devant A, Dutour A, Alessi MC, Bastard JP, Clément K, Guerre-Millo M: Potential contribution of adipose tissue to elevated serum cystatin C in human obesity. Obesity (Silver Spring) 2009;17:2121-2126.
36. Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L: Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med 2005;118:1416.
37. Leung-Tack J, Tavera C, Martinez J, Colle A: Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation 1990;14:247-258.
38. Leung-Tack J, Tavera C, Gensac MC, Martinez J, Colle A: Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res 1990;188:16-22.
39. Natali A, Pucci G, Boldrini B, Schillaci G: Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol 2009;22:29-38.
40. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L: Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110:2342-2348.
41. Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, Balko JA, Gupta S, Mammen PP, Drazner MH, Markham DW: Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail 2009;2:98-104.
42. Gu FF, Lü SZ, Chen YD, Zhou YJ, Song XT, Jin ZN, Liu H: Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound. Chin Med J (Engl) 2009;122:2820-2826.